-
Innovation Ranking
Innovation Ranking – Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc (Rocket Pharma), formerly Inotek Pharmaceuticals Corp is a clinical-stage biopharmaceutical company. It focuses on gene therapies for rare and devastating diseases. The company has three clinical-stage ex vivo lentiviral vector (“LVV”) programs which include programs for Fanconi Anemia (“FA”), a genetic defect in the bone marrow that reduces the production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I (“LAD-I”), a genetic disorder that causes the immune system to malfunction, and Pyruvate...
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Volrustomig
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Volrustomig report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Thematic Analysis
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 – Top Themes and Predictions – Thematic Intelligence
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 Theme and Predictions Report Overview Total M&A deal value in the technology, media, and telecom (TMT) sector declined 46% in 2023, compared to the previous year. Software and services accounted for over 48% share of the total M&A deal value in 2023. The ‘Global Tech, Media, And Telecom (TMT) M&A Deals 2023 Theme and Predictions Report’ analyzes the top disruptive themes that drove M&A activity in the technology, media, and telecom (TMT)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MET-5 in Hypertriglyceridemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MET-5 in Hypertriglyceridemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MET-5 in Hypertriglyceridemia Drug Details: MET-5 is under development for the treatment of...
-
Analyst Opinions
Agile IT – How Software-Defined Everything (SDx) Transforms Enterprise Fabric
Software-Defined Everything (SDx) Technology Overview Software-Defined Everything (SDx) is the key to managing enterprise IT infrastructure challenges. SDx technologies enable dynamic resource allocation, centralized management, security enhancement, agile provisioning, and integration with modern applications, fostering infrastructure efficiency and resilience. "Agile IT - How Software-Defined Everything (SDx) Transforms Enterprise Fabric" innovation radar report explores the pervasive influence of software-defined technologies across various sectors such as automotive, technology, telecom, aerospace & defense, manufacturing, energy & power, and consumer & retail. This report...
-
Thematic Analysis
Banking Predictions for 2024 – Thematic Intelligence
Exploring in-depth trends and insights from the ‘Banking Predictions for 2024’ report will enable you to: Analyze the major themes that will impact the banking industry in 2024. Identify the top 20 themes impacting the banking industry – artificial intelligence, cybersecurity, the future of work, cloud computing, blockchain and cryptocurrencies, fintech, internet of things, big data, social media, financial wellness, digital lending, digital banking, conversational platforms, personalization, data privacy, and open banking. Understand a wide range of disruptive themes that...
-
Product Insights
NewCardiomyopathy – Drugs In Development, 2024
Empower your strategies with our Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions. Cardiomyopathy a disease of the heart muscle, where the walls of the heart chambers have become stretched, thickened or stiff. This affects the heart's ability to pump blood around the body. Most types of cardiomyopathy are inherited. It can also be caused by other conditions, or risk factors, but for some people the cause is unknown. Cardiomyopathy can affect people of all ages...
-
Product Insights
NewLeukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2024
Empower your strategies with our Leukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2024 report and make more profitable business decisions. Leukocyte disorders, also known as white blood cell disorders, encompass a range of conditions that involve abnormalities in the production, function, or levels of white blood cells (leukocytes). White blood cells play a crucial role in the immune system, defending the body against infections, diseases, and foreign invaders. The Leukocyte Disorders (White Blood Cell Disorders) drugs in development...
-
Product Insights
NewDilated Cardiomyopathy – Drugs In Development, 2024
Empower your strategies with our Dilated Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions. Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include fatigue and weakness, shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention, and swelling (edema) in legs, ankles, and...